Applied Genetic Technologies (AGTC) Tops Q2 EPS by 45c

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 11/3/2026

1. AAPL
2. PLTR
3. VRTX
4. CHKP
5. ON
6. CRWD
7. HNGE
8. INSP
9. CVI
10. SPY

Go back to Applied Genetic Technologies (AGTC) Tops Q2 EPS by 45c

AGTC Announces Financial Results and Business Update for the Quarter Ended December 31, 2018

February 7, 2019 7:00 AM EST

GAINESVILLE, Fla., and CAMBRIDGE, Mass., Feb. 07, 2019 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (Nasdaq: AGTC), a biotechnology company conducting human clinical trials of adeno-associated virus (AAV)-based gene therapies for the treatment of rare diseases, today announced financial results for the quarter ended December 31, 2018.

AGTC is positioned for significant progress in 2019, including data readouts from our achromatopsia B3, achromatopsia A3 and X-linked retinitis pigmentosa clinical trials, said Sue Washer, President and CEO of AGTC. We also expect that our optogenetics partner, Bionic Sight, will file an Investigational... More